-

QIAGEN to Launch QuantiFERON SARS-CoV-2 For Research Into Causes, Spread and Control of COVID-19 Through T-cell Response

T-cell response has the potential to give a clearer picture of immunity and course of illness 

• T-cell response to SARS-CoV-2 may decline less rapidly than antibodies

• Potentially vital tool for research into immune response and vaccination efficacy

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of its QuantiFERON SARS-CoV-2 RUO solution that can detect T-cell responses of the human immune system to the pathogen that causes COVID-19, which could help researchers find out more about immunity levels and disease progression.

Studies suggest that T-cell response to SARS-CoV-2 declines much more slowly than antibody response, which presents several benefits to researchers who want to push beyond the existing detection of active infections to screen for potential courses of the illness and long-term immune responses to it. QIAGEN’s QuantiFERON SARS-CoV-2 Research Use Only (RUO) solution could be a valuable tool in this research.

There is also growing evidence that T-cell response gives a reliable indication of how severe the course of an illness triggered by SARS-CoV-2 will be in infected patients, and how immune those who have recovered remain months – possibly even years – after having been infected.

QuantiFERON SARS-CoV-2 RUO is a flexible, modular system designed to meet a wide range of research demands. It is based on QIAGEN’s easy-to-use QuantiFERON technology, pioneered in the QuantiFERON-TB Gold Plus test for latent tuberculosis and recognized worldwide for its ability to detect interferon gamma that T-cells release upon contact with certain pathogens.

QuantiFERON SARS-CoV-2 RUO is a crucial addition to QIAGEN’s growing COVID-19 portfolio that already provides sample-preparation technology, infection testing with polymerase chain reaction (PCR) technology, antibody and antigen tests, enzymes and automation solutions.

Please find the full press release here

Contacts

QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826

Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

QIAGEN N.V.

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)

Release Summary
QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response
Release Versions
$Cashtags

Contacts

QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826

Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

Social Media Profiles
More News From QIAGEN N.V.

QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio. For Q1 2026, preliminary net sales were $492 million, up 2% on a reporte...

QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and molecular diagnostics. “Cancer research and molecular diagnostics are increasingl...

QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

HILDEN, Germany & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The launch of this new QIAstat-Dx panel coincides with the ESCMID Global 2026 Congress in Munich (April 17–21), where QIAGEN will highlight its broad infectious disease portfolio, including QIAstat-Dx, the QuantiFERON-TB Gold Plus...
Back to Newsroom